Natco Pharma is currently trading at Rs 532.00, up by 12.10 points or 2.33% from its previous closing of Rs 519.90 on the BSE.
The scrip opened at Rs 529.95 and has touched a high and low of Rs 538.00 and Rs 522.00 respectively. So far 13087 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 623.60 on 05-Jan-2016 and a 52 week low of Rs. 265.98 on 26-Feb-2015.
Last one week high and low of the scrip stood at Rs. 560.00 and Rs. 458.05 respectively. The current market cap of the company is Rs. 9243.43 crore.
The promoters holding in the company stood at 51.31% while Institutions and Non-Institutions held 26.41% and 22.28% respectively.
Natco Pharma has signed a nonexclusive, royalty free licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Bristol-Myers Squibb’s chronic hepatitis C medicine – Daclatasvir Dihydrochloride (Daclatasvir).
Daclatasvir, discovered and developed by Bristol-Myer Squibb, is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets. The company will market generic Daclatasvir under its own brand NATDAC, and through its strategic partners in India.
This agreement allows the company to expand access to these chronic hepatitis C medicines in 112 developing countries. Under the license, Natco can set its own price for the generic products it produces.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
- See more at:
http://money.livemint.com/news/market/equity/movers-today/natco-pharma-gains-on-inking-agreement-with-mpp-and-bristol-myers-squibb-for-daclatasvir--423309.aspx#sthash.YrgNihBc.dpuf
The scrip opened at Rs 529.95 and has touched a high and low of Rs 538.00 and Rs 522.00 respectively. So far 13087 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 623.60 on 05-Jan-2016 and a 52 week low of Rs. 265.98 on 26-Feb-2015.
Last one week high and low of the scrip stood at Rs. 560.00 and Rs. 458.05 respectively. The current market cap of the company is Rs. 9243.43 crore.
The promoters holding in the company stood at 51.31% while Institutions and Non-Institutions held 26.41% and 22.28% respectively.
Natco Pharma has signed a nonexclusive, royalty free licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Bristol-Myers Squibb’s chronic hepatitis C medicine – Daclatasvir Dihydrochloride (Daclatasvir).
Daclatasvir, discovered and developed by Bristol-Myer Squibb, is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets. The company will market generic Daclatasvir under its own brand NATDAC, and through its strategic partners in India.
This agreement allows the company to expand access to these chronic hepatitis C medicines in 112 developing countries. Under the license, Natco can set its own price for the generic products it produces.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
|
|
No comments:
Post a Comment